Table 2.
The relationship between clinicopathological characteristics, computed tomography‐derived body composition, and survival in patients undergoing elective surgery for colorectal cancer (n = 650): univariate survival analysis
| Characteristic | n = 650 (%) | Overall survival HR (95% CI) | P‐value | |
|---|---|---|---|---|
| Clinicopathological | ||||
| Age | ≤65 | 234 (36.0) | 1.64 (1.29–2.08) | <0.001 |
| 65–74 | 251 (38.6) | |||
| >74 | 165 (25.4) | |||
| Sex | Female | 296 (45.5) | 1.19 (0.83–1.70) | 0.351 |
| Male | 354 (54.5) | |||
| ASA score | 1 | 141 (21.7) | 1.56 (1.23–1.97) | <0.001 |
| 2 | 297 (45.7) | |||
| 3 | 193 (29.7) | |||
| 4 | 19 (2.9) | |||
| Laparoscopic surgery | No | 407 (62.6) | 0.68 (0.45–1.03) | 0.072 |
| Yes | 243 (37.4) | |||
| TNM | 0 | 14 (2.2) | 1.67 (1.31–2.14) | <0.001 |
| I | 155 (23.8) | |||
| II | 263 (40.5) | |||
| III | 218 (33.5) | |||
| Venous invasion | No | 266 (40.9) | 1.26 (0.87–1.82) | 0.217 |
| Yes | 384 (59.1) | |||
| Tumour location | Right and transverse | 247 (38.0) | 0.84 (0.58–1.23) | 0.373 |
| Left | 145 (22.3) | |||
| Rectum | 237 (36.5) | |||
| Total and subtotal | 21 (3.2) | |||
| Adjuvant chemotherapy | No | 463 (71.2) | 0.70 (0.45–1.08) | 0.102 |
| Yes | 187 (28.8) | |||
| Systemic inflammation | ||||
| mGPS | 0 | 499 (76.8) | 1.55 (1.25–1.91) | <0.001 |
| 1 | 63 (9.7) | |||
| 2 | 88 (13.5) | |||
| NLR | ≤3 | 369 (56.8) | 1.40 (0.98–1.99) | 0.066 |
| >3 | 281 (43.2) | |||
| NPS | 0 | 568 (87.4) | 1.66 (1.16–2.36) | 0.005 |
| 1 | 67 (10.3) | |||
| 2 | 15 (2.3) | |||
| Body composition | ||||
| BMI (kg/m2) | <25 | 29 (4.5) | 0.60 (0.39–0.91) | 0.0154 |
| ≥25 | 190 (29.2) | |||
| High SFI | No | 116 (17.8) | 0.60 (0.40–0.89) | 0.011 |
| Yes | 534 (82.2) | |||
| Visceral obesity | No | 177 (27.2) | 0.68 (0.47–0.98) | 0.040 |
| Yes | 473 (72.8) | |||
| Low SMI (sarcopenia) | ||||
| SMI (Martin) | No | 367 (56.5) | 1.74 (1.21–2.49) | 0.003 |
| Yes | 283 (43.5) | |||
| SMI (Dolan BMI ≥ 25) | No | 371 (57.1) | 1.77 (1.24–1.54) | 0.002 |
| Yes | 279 (42.9) | |||
| SMI (Caan) | No | 313 (48.2) | 1.58 (1.09–2.28) | 0.016 |
| Yes | 337 (51.8) | |||
| SMI (Dolan BMI ≥ 30) | No | 386 (59.4) | 1.60 (1.12–2.28) | 0.010 |
| Yes | 264 (40.6) | |||
| Low SMD (myosteatosis) | ||||
| SMD (Martin) | No | 258 (39.7) | 1.84 (1.25–2.72) | 0.002 |
| Yes | 392 (60.3) | |||
| SMD (Dolan BMI ≥ 25) | No | 343 (52.8) | 1.57 (1.10–2.25) | 0.013 |
| Yes | 307 (47.2) | |||
| SMD (Xiao) | No | 309 (47.5) | 1.54 (1.07–2.22) | 0.020 |
| Yes | 341 (52.5) | |||
| SMD (Dolan Male/Female) | No | 304 (46.8) | 1.58 (1.10–2.27) | 0.014 |
| Yes | 346 (53.2) | |||
BMI, body mass index; CI, confidence interval; HR, hazard ratio; mGPS, modified Glasgow prognostic score; NLR, neutrophil lymphocyte ratio; NPS, neutrophil‐platelet score; SFI, subcutaneous fat index; SMD, skeletal muscle density; SMI, skeletal muscle index.